Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
BETAHISTINE DIHYDROCHLORIDE
McDermott Laboratories Ltd t/a Gerard Laboratories
BETAHISTINE DIHYDROCHLORIDE
8 Milligram
Tablets
Product subject to prescription which may be renewed (B)
Authorised
0000-00-00
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT VERTIGON 8 MG TABLETS VERTIGON 16 MG TABLETS (betahistine dihydrochloride) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Vertigon is and what it is used for 2. What you need to know before you take Vertigon 3. How to take Vertigon 4. Possible side effects 5. How to store Vertigon 6. Contents of the pack and other information 1. WHAT VERTIGON IS AND WHAT IT IS USED FOR Vertigon belongs to a group of medicines known as histamine analogues. It works by improving blood flow in the inner ear, which reduces the build up of pressure. It is this pressure in the inner ear which is thought to cause nausea, vertigo (dizziness), tinnitus (ringing in the ears) and hearing loss suffered by people with Meniere’s disease. Vertigon is used in the treatment of these symptoms. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE VERTIGON DO NOT TAKE VERTIGON: • if you are allergic to betahistine dihydrochloride or any of the other ingredients of this medicine (listed in section 6) • if you are taking an antihistamine to treat allergy. Vertigon may lower the effect of antihistamines • if you have a tumour of the adrenal gland called a Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Vertigon 8 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Betahistine dihydrochloride 8 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet. White, 7.0 mm, round, flat bevel edged tablet marked “BH 8” on one side and “G” on the reverse. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Betahistine is indicated for the treatment of vertigo, tinnitus, hearing loss and nausea associated with Ménière’s syndrome. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology: Adults: (including the elderly) Initial oral treatment is 8 mg to 16 mg three times daily, taken with food. Maintenance doses are generally in the range 24 - 48 mg daily. Dosage can be adjusted to suit individual patient needs. Paediatric Population: Betahistine tablets are not recommended for use in children below 18 years due to insufficient data on safety and efficacy. 4.3 CONTRAINDICATIONS Phaeochromocytoma. As betahistine is a synthetic analogue of histamine it may induce the release of catecholamines from the tumour resulting in severe hypertension. Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Concurrent use with antihistamines (see section 4.5). 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Caution is advised in the treatment of patients with peptic ulcer or a history of peptic ulceration, because of the occasional dyspepsia encountered in patients on betahistine. Caution should be exercised in patients with bronchial asthma. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 15/05/2014_ _CRN 2141673_ _page number: 1_ Patients with bronchial asthma and history of peptic ulcer Read the complete document